Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

CTA granted for CAR-T cell therapy for multiple myeloma

The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...

2026 Snow Fellowship recipients to receive $24m in biomedical funding

Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...

Content from other channels on our network

Food packaging testing supports Atlantic crossing victory

Seprify and BIOGRUND develop titanium dioxide-free tablet coating for nutraceuticals

Foodmach invests in A&RT to help drive growth

UQ opens FaBA MakerSpace for food innovations

Seedlab Australia's Bootcamp reveals a shift to family-first food

UNSW hydrogen fuel cell design could unlock key clean energy technology

NSW introduces mandatory regulations for battery manufacturers

Is machine monitoring worthwhile?

A merging of flavours: Unilever Foods and McCormick

Government brings forward $6.15bn to support manufacturing

"Targeted supports" launched for former patients of Simon Gordon

Purpose-built acute distress unit within Westmead ED announced

EMR solutions must support evolution and change

An era for AI agents: why healthcare leaders can't afford to manage governance on spreadsheets

Works completed on two new Victorian aged care facilities